Interest in psychedelic therapy has grown rapidly in recent years, but many people are surprised to learn that ketamine, MDMA, and psilocybin are very different treatments. They have different legal status, different research focuses, different treatment models, and different clinical goals.
If you’re exploring psychedelic therapy in California, understanding these differences can help you better interpret what you read in the news and understand which treatments are currently available versus those that remain under investigation.
Ketamine Therapy
Unlike MDMA and psilocybin, ketamine therapy is already legally available in California when prescribed and administered by licensed medical providers for appropriate patients.
Originally developed as an anesthetic, ketamine has gained attention over the past decade because research suggests it may help some individuals with conditions such as:
- Treatment-resistant depression
- Major depressive disorder
- Suicidal ideation
- Certain anxiety disorders
- Chronic pain (in some medical settings)
Ketamine may be administered through intravenous (IV) infusion, intramuscular injection, nasal spray, or oral formulations depending on the provider and treatment plan.
Some clinics focus primarily on the medical administration of ketamine, while others incorporate psychotherapy before, during, or after treatment. These approaches are sometimes referred to as ketamine-assisted psychotherapy (KAP).
For a more detailed overview, read our guide to Ketamine Therapy in California.
MDMA-Assisted Therapy
MDMA-assisted therapy for PTSD has become one of the most widely discussed areas of psychedelic research.
Unlike ketamine, MDMA is not currently approved for routine therapeutic use outside approved research settings.
Researchers have primarily studied MDMA in combination with psychotherapy rather than as a medication alone. Treatment generally includes:
- Comprehensive psychological screening
- Multiple preparation sessions
- One or more extended medication sessions
- Follow-up integration therapy
During research studies, participants often describe increased emotional openness, reduced fear responses, and an improved ability to process traumatic memories alongside trained therapists.
Current research has focused primarily on:
- PTSD
- Military veterans
- First responders
- Survivors of significant trauma
Learn more in our guides to MDMA Therapy in California and How MDMA Therapy Works for PTSD.
Psilocybin Therapy
Psilocybin is the naturally occurring psychedelic compound found in certain mushroom species. While public interest often focuses on “magic mushrooms,” clinical researchers study purified psilocybin in carefully controlled therapeutic settings.
Like MDMA, psilocybin therapy is not currently available as a routine clinical treatment in California, although research continues to expand.
Researchers are studying psilocybin for several conditions, including:
- Major depressive disorder
- Treatment-resistant depression
- Anxiety associated with serious illness
- End-of-life psychological distress
- Substance use disorders
- Obsessive-compulsive disorder (ongoing research)
Rather than focusing primarily on trauma processing, many psilocybin studies explore how profound psychological experiences may support emotional flexibility, insight, and changes in mood when combined with psychotherapy.
Learn more in our guide to Psilocybin Therapy in California.
Session Lengths and Treatment Experience
Although all three therapies involve careful preparation and professional oversight, the treatment experiences differ considerably.
Ketamine
Ketamine sessions are generally the shortest. Depending on the treatment method, patients may spend roughly one to two hours in the clinic, with the medication effects lasting a relatively brief period. Some providers incorporate psychotherapy during or after treatment.
MDMA
MDMA-assisted therapy sessions in research settings are substantially longer, often lasting six to eight hours or more. These sessions emphasize trauma processing, emotional safety, and continuous therapeutic support.
Psilocybin
Psilocybin sessions also tend to be lengthy, often lasting six to eight hours. Participants typically remain in a carefully designed therapeutic environment with trained clinicians available throughout the experience.
Because of these differences, the therapies should not be viewed as interchangeable simply because they are sometimes grouped under the broader term “psychedelic therapy.”
Legal Status in California
One of the biggest distinctions between these therapies is their current legal availability.
Ketamine
- Legally available when prescribed and administered by licensed medical professionals.
MDMA
- Not currently approved for routine clinical treatment.
- Primarily available through research studies and clinical trials.
Psilocybin
- Also not approved for routine therapeutic use in California.
- Currently limited largely to research settings.
As laws and regulatory decisions continue to evolve, access to these treatments may change over time.
Different Therapeutic Models
The therapeutic structure also differs among these treatments.
Ketamine care may be delivered by medical clinics that focus primarily on medication administration, while other providers combine ketamine with psychotherapy.
MDMA research places psychotherapy at the center of treatment. Preparation, the medication session itself, and follow-up integration are all considered essential components of the therapeutic model.
Psilocybin research similarly emphasizes extensive preparation and integration rather than viewing the medication experience alone as the treatment.
In every case, researchers generally view the medication as one part of a broader therapeutic process rather than a stand-alone solution.
Why These Treatments Shouldn’t Be Compared Too Simply
Because all three therapies receive media attention, it’s easy to assume they produce similar experiences or treat the same conditions. The reality is much more nuanced.
Each treatment differs in:
- Mechanism of action
- Current legal status
- Research evidence
- Target conditions
- Session structure
- Therapeutic goals
- Duration of effects
Someone exploring options for treatment-resistant depression may encounter very different evidence than someone seeking care for PTSD or another condition.
For that reason, treatment decisions should always involve qualified medical and mental health professionals who can evaluate an individual’s circumstances and discuss current evidence, risks, and available options.
Looking Ahead
Research into psychedelic-assisted therapies continues to expand, and each of these treatments may play a different role in the future of mental health care.
At present:
- Ketamine is the only one of the three that is legally available in California through licensed providers.
- MDMA remains most closely associated with PTSD research and trauma-focused psychotherapy.
- Psilocybin continues to be studied for depression, anxiety, end-of-life distress, and several other psychiatric conditions.
As additional clinical trials are completed and regulatory decisions evolve, our understanding of where each therapy may fit into mental health treatment will likely continue to grow.